Close Menu
Despite a delay in pharmaceutical spending and other “challenging economic conditions,” Waters this week said that researchers continue to express strong interest in the company’s Acquity UPLC and Synapt High Definition mass spectrometer.
 
Company officials made those remarks as Waters released its first-quarter earnings, which showed that revenues rose 12 percent to $371.1 million from $330.8 million a year ago, and profits surged 22 percent to $68.5 million from $56 million last year.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.